Eugênio Cersósimo
YOU?
Author Swipe
View article: Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes
Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes Open
Objective: To examine the effects of SGLT2i alone or with GLP-1 RA on β-cell function in type 2 diabetes [T2D]. Hypothesis: SGLT-2i, combined with GLP-1 RA, provides superior improvement in β-cell function than either agent alone. Research…
View article: Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes
Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes Open
Objective: To examine the effects of SGLT2i alone or with GLP-1 RA on β-cell function in type 2 diabetes [T2D]. Hypothesis: SGLT-2i, combined with GLP-1 RA, provides superior improvement in β-cell function than either agent alone. Research…
View article: Effect of Hyperketonemia on Myocardial Function in Patients With Heart Failure and Type 2 Diabetes
Effect of Hyperketonemia on Myocardial Function in Patients With Heart Failure and Type 2 Diabetes Open
We examined the effect of increased levels of plasma ketones on left ventricular (LV) function, myocardial glucose uptake (MGU), and myocardial blood flow (MBF) in patients with type 2 diabetes (T2DM) with heart failure. Three groups of pa…
View article: Effect of Hyperketonemia on Myocardial Function in Patients with Heart Failure and Type 2 Diabetes
Effect of Hyperketonemia on Myocardial Function in Patients with Heart Failure and Type 2 Diabetes Open
We examined the effect of increased plasma ketones on left ventricular (LV) function, myocardial glucose uptake (MGU), and myocardial blood flow (MBF) in type 2 diabetes (T2DM) patients with heart failure (HF). Three groups (I,II,III) of T…
View article: Effect of Hyperketonemia on Myocardial Function in Patients with Heart Failure and Type 2 Diabetes
Effect of Hyperketonemia on Myocardial Function in Patients with Heart Failure and Type 2 Diabetes Open
We examined the effect of increased plasma ketones on left ventricular (LV) function, myocardial glucose uptake (MGU), and myocardial blood flow (MBF) in type 2 diabetes (T2DM) patients with heart failure (HF). Three groups (I,II,III) of T…
View article: Effect of weight-maintaining ketogenic diet on glycemic control and insulin sensitivity in obese T2D subjects
Effect of weight-maintaining ketogenic diet on glycemic control and insulin sensitivity in obese T2D subjects Open
Introduction Low carbohydrate ketogenic diets have received renewed interest for the treatment of obesity and type 2 diabetes. These diets promote weight loss, improve glycemic control, and reduce insulin resistance. However, whether the i…
View article: Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2DM and NGT Subjects
Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2DM and NGT Subjects Open
Acute and chronic SGLT-2 inhibition increase endogenous glucose production (EGP). However, the organ - liver versus kidney - responsible for the increase in EGP has not been identified. 20 T2DM and 12 NGT subjects received [3-3H]-glucose i…
View article: Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2DM and NGT Subjects
Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2DM and NGT Subjects Open
Acute and chronic SGLT-2 inhibition increase endogenous glucose production (EGP). However, the organ - liver versus kidney - responsible for the increase in EGP has not been identified. 20 T2DM and 12 NGT subjects received [3-3H]-glucose i…
View article: Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects
Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects Open
Acute and chronic sodium–glucose cotransporter 2 (SGLT-2) inhibition increases endogenous glucose production (EGP). However, the organ—liver versus kidney—responsible for the increase in EGP has not been identified. In this study, 20 subje…
View article: Current Risk Management Strategies in Type 2 Diabetes
Current Risk Management Strategies in Type 2 Diabetes Open
Natural history and Pre-diabetes – Type-2 diabetes (T2DM) is a chronic disease with various metabolic and hormonal disorders derived from genetic and environmental factors that compromise organs and functional systems. Prevention must be i…
View article: FRI607 SGLT2 Inhibition Improves Muscle Oxidative Capacity And Its Relationship With Cardiac Performance In Patients With T2D And Heart Failure
FRI607 SGLT2 Inhibition Improves Muscle Oxidative Capacity And Its Relationship With Cardiac Performance In Patients With T2D And Heart Failure Open
Disclosure: Y. Qin: None. N.D. Sanchez: None. A.J. Moody: None. F.M. Acosta: None. S. Neppala: None. M. Brown: None. H. Honka: None. B. Todd: None. L.A. Cruz Moreno: None. A.R. Stepanenko: None. S.E. Espinoza: None. N. Musi: None. C. Tripl…
View article: Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes
Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes Open
Aims To examine the effect of pioglitazone on epicardial (EAT) and paracardial adipose tissue (PAT) and measures of diastolic function and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). Methods Twelve patients with T…
View article: Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects
Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects Open
Bromocriptine-QR is a sympatholytic dopamine D2 agonist for the treatment of type 2 diabetes that has demonstrated rapid (within 1 year) substantial reductions in adverse cardiovascular events in this population by as yet incompletely deli…
View article: FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes
FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes Open
In patients with T2D treated with a combination of metformin/pioglitazone/exenatide (triple therapy), we observed reduced total and bioactive plasma FGF21 levels and a relative increase in the proportion of circulating bioactive FGF21 comp…
View article: Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose
Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose Open
OBJECTIVE To examine the effect of SGLT2 inhibitors (SGLT2i) on endogenous glucose production (EGP) in patients with type 2 diabetes after an oral glucose load. RESEARCH DESIGN AND METHODS Forty-eight patients with type 2 diabetes received…
View article: Author response for "Combination Therapy with Pioglitazone/Exenatide Metformin Reduces the Prevalence of Hepatic Fibrosis and Steatosis: The Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes ( EDICT ) Trial"
Author response for "Combination Therapy with Pioglitazone/Exenatide Metformin Reduces the Prevalence of Hepatic Fibrosis and Steatosis: The Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes ( EDICT ) Trial" Open
Aim To compare the efficacy of triple therapy (metformin/exenatide/pioglitazone) versus stepwise conventional therapy (metformin -> glipizide -> glargine insulin) on liver fat content and hepatic fibrosis in newly diagnosed, drug-naive pat…
View article: Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes
Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes Open
Type 2 diabetes management continues to increase in complexity as more pharmacologic medication classes become available and high-quality clinical trials are completed. Because many antihyperglycemic agents could be appropriate for a given…
View article: The evidence behind early aggressive multi-drug treatment in type 2 diabetes
The evidence behind early aggressive multi-drug treatment in type 2 diabetes Open
In the past few decades, the emergence of novel information from rigorous clinical trials and observational studies has reset the priorities regarding the management of type 2 diabetes [T2D].Most recent results have focused on therapeutic …
View article: Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT Open
OBJECTIVE To compare the long-term efficacy of initiating therapy with metformin/pioglitazone/exenatide in patients with new-onset type 2 diabetes mellitus (T2DM) versus sequential addition of metformin followed by glipizide and insulin. R…
View article: Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT Open
Objective: To compare the long term efficacy of initiating therapy with metformin/pioglitazone/exenatide in new onset T2DM patients versus sequential addition of metformin followed by glipizide and insulin. Research Design and
View article: Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT Open
Objective: To compare the long term efficacy of initiating therapy with metformin/pioglitazone/exenatide in new onset T2DM patients versus sequential addition of metformin followed by glipizide and insulin. Research Design and
View article: Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM
Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM Open
Aim To examine the effect of combination therapy with canagliflozin plus liraglutide versus each agent alone on beta cell function in type 2 diabetes mellitus (T2DM) patients. Research Design and Methods A total of 45 poorly controlled (Hb…
View article: Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin
Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin Open
OBJECTIVE To examine the mechanisms responsible for improved glycemia with combined sodium–glucose cotransporter 2 inhibitor (SGLT2i) plus dipeptidyl peptidase 4 inhibitor therapy in type 2 diabetes. RESEARCH DESIGN AND METHODS Fifty-six p…
View article: Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes
Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes Open
OBJECTIVE To examine the effect of combination therapy with canagliflozin plus liraglutide on HbA1c, endogenous glucose production (EGP), and body weight versus each therapy alone. RESEARCH DESIGN AND METHODS Forty-five patients with poorl…
View article: Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion
Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion Open
OBJECTIVE Sodium–glucose cotransporter 2 (SGLT2) inhibition causes an increase in endogenous glucose production (EGP). However, the mechanisms are unclear. We studied the effect of SGLT2 inhibitors on EGP in subjects with type 2 diabetes (…
View article: Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors Open
Sodium–glucose cotransport 2 inhibitors (SGLT2i) lower plasma glucose but stimulate endogenous glucose production (EGP). The current study examined the effect of dapagliflozin on EGP while clamping plasma glucose, insulin, and glucagon con…
View article: Challenges of Diabetes Care in Older People With Type 2 Diabetes and the Role of Basal Insulin
Challenges of Diabetes Care in Older People With Type 2 Diabetes and the Role of Basal Insulin Open
IN BRIEF The use of long-acting basal insulin analogs is a recommended strategy in older people with diabetes because of their lower risk of hypoglycemia compared to intermediate-acting insulins. In this article, we review the results from…
View article: Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors
Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors Open
Background & Introduction: The advent of the sodium-glucose cotransporter-2 inhibitors [SGLT-2i] provides an additional tool to combat diabetes and complications. The use of SGLT-2i leads to effective and durable glycemic control with impo…
View article: Glucose lowering and vascular protective effects of cycloset added to <scp>GLP</scp>‐1 receptor agonists in patients with type 2 diabetes
Glucose lowering and vascular protective effects of cycloset added to <span>GLP</span>‐1 receptor agonists in patients with type 2 diabetes Open
Summary Objective To determine the glucose‐lowering mechanism of action and the effects of a quick‐release bromocriptine‐ QR , a D2‐dopamine agonist (Cycloset) on vascular function in patients with type 2 diabetes (T2D). Study design and m…
View article: Impaired left ventricular diastolic function in T2<scp>DM</scp> patients is closely related to glycemic control
Impaired left ventricular diastolic function in T2<span>DM</span> patients is closely related to glycemic control Open
Summary Background Left ventricular ( LV ) diastolic dysfunction commonly is observed in individuals with type 2 diabetes mellitus (T2 DM ). We employed transthoracic echocardiography ( TTE ) and cardiac magnetic resonance imaging ( CMRI )…